Japan-based Fujirebio Holdings and Indian firm Agappe Diagnostics have entered into an agreement of Contract Development and Manufacturing Organization (CDMO) partnership for cartridge-based chemiluminescence immunoassay (CLIA) system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121.

Notably, the analysers and reagents will be sold under Agappe’s brand, making Agappe the first Indian local company with a complete Chemiluminescence Solution comprising locally manufactured reagents.

In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progress, including the signing of a Supply and License Agreement in March 2023. Agappe is at the advanced stages of technical transfer from Fujirebio, enabling them to manufacture Chemiluminescence Reagents using Fujirebio’s technology and materials.

This initiative is set to be impactful, involving the phased launches of the entire range of more than 30 parameters across diverse segments, including Oncology, Thyroid, Cardiac, Fertility, and Infectious Diseases. Fujirebio’s innovative biomarkers for Alzheimer’s disease and other neurodegenerative disease are also in the scope.

Fujirebio will supply the equipment Mispa i60 & i121 and reagent raw materials, while Agappe will develop and manufacture dedicated reagents for the equipment, complying with all regulatory formalities.